Table 1.
ERCC2 Asp312Asn and ERCC2 Lys751Gln polymorphisms and breast cancer risk
| Genotype | Cases (%) | Controls (%) | OR (95%CI) | ORadj* (95%CI) | P value |
| ERCC2 Asp312Asn | |||||
| Asp/Asp | 403 (45) | 458 (46) | 1.00 (reference) | 1.00 (reference) | |
| Asp/Asn | 383 (42) | 418 (42) | 1.04 (0.86–1.26) | 1.06 (0.93–1.21) | |
| Asn/Asn | 118 (13) | 118 (12) | 1.14 (0.85–1.52) | 1.12 (0.86–1.46) | 0.68 |
| ERCC2 Lys751Gln | |||||
| Lys/Lys | 121 (13) | 119 (11) | 1.00 (reference) | 1.00 | |
| Lys/Gln | 419 (46) | 446 (44) | 0.92 (0.69–1.23) | 0.92 (0.80–1.05) | |
| Gln/Gln | 368 (40) | 430 (43) | 0.84 (0.63–1.12) | 0.84 (0.64–1.09) | 0.43 |
* Adjusted for age